Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on September 10, 2026, that includes a response to the Final Office Action mailed May 12, 2026, has been entered. Claims 1, 9, 15, and 25 have been amended; and claims 2, 5, 7, 19 and 20 have been canceled. Claims 4, 6, 11-18, and 24 have been withdrawn. Claims 1, 3, 8-10, 21-23, and 25 are under examination.
Withdrawal of Prior Claim Rejections - 35 USC § 112(d)
Claim 5 has been canceled. Therefore, the 35 USC 112(d) rejection of claim 5, presented in the Final Office Action mailed May 12, 2026, is hereby withdrawn.
Claim Objections
Claims 1, 6 and 24 are objected to because of the following:
i) In claim 1, the expression “at least one carrier material comprising at least one material selected from” is awkward and redundant. Applicant is advised to amend the expression to “at least one carrier material selected from”.
ii) Claims 6 and 24 contain improper status identification. These claims have been withdrawn, and thus should properly be identified accordingly as “withdrawn”.
Appropriate correction is required.
Obviousness-Type Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1, 3, 8-10, 21-23, and 25 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5 and 16-19 of copending Application No. 18/713,056.
Applicant’s elected subject matter is directed to an antimicrobial “material” comprising spherical particles with a diameter of at most 5 µm comprising a cellulose carrier at least partially coated with ruthenium oxide and silver oxide.
Claims 1-5 and 16-19 of copending Application No. 18/713,056 disclose an antimicrobial “material” comprising particles comprising a cellulose carrier at least partially coated with ruthenium oxide and silver oxide.
Although the claims at issue are not identical, they are not patentably distinct from each other because the disclosure of copending Application No. 18/713,056 provides that by “particle” is meant “all possible particle shapes and sizes” (paragraph 0042), including those with a length, diameter and/or circumference greater than 100 nanometers (nm) (paragraph 0028). This would include within the scope of the purview spherical particles; and a diameter “greater than 100 nm” is not patentably distinct from “a diameter of at most 5 µm”.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1, 3, 8-10, 21-23, and 25 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 1 first stipulates that the hybrid material “can be integrated into substances and/or coating materials for producing an antimicrobial effect”, implying that the antimicrobial effect is somehow dependent on being integrated with other substances and/or coating materials, but then claim 1 later stipulates that the first metal and the second metal establish half cells, and that the hybrid material itself produces the antimicrobial effect, implying that the half cells themselves somehow provide the antimicrobial effect independent of being integrated into other substances and/or coating materials. One of ordinary skill in the art thus cannot definitively ascertain the metes and bounds of the claimed subject matter.
Claim 25, which depends from claim 1, stipulates in a wherein clause that “the established half cells are short-circuited in the presence of water and oxygen thereby producing the antimicrobial effect”, which renders the clam indefinite for the following reasons:
1. Claim 1 first stipulates in the preamble that the claimed “material” is “provided as an additive…for producing an antimicrobial effect”. One of ordinary skill in the art cannot definitively ascertain whether or not the claimed material itself necessarily contains water and oxygen, or, alternatively, whether the composition in which the claimed “material” is employed as an additive in an intended use is necessarily limited to aqueous compositions that contain both water and oxygen, or whether compositions that contain water and oxygen are entirely optional, but when employed as an additive in such compositions, the effect is as described.
2. Claim 1 states that the hybrid material comprises a first and second metal that establish half cells. Claim 1 then states in a wherein clause that “the hybrid material produces the antimicrobial effect”. But claim 25 states that the antimicrobial effect is only produced when the half cells are short circuited, which is arriving at a different state than the claimed hybrid material, in which the half cells are established. One of ordinary skill in the art cannot definitively ascertain the metes and bounds of the claimed subject matter.
Claims 3, 5, 8-10, 21-23, and 25 are (also) indefinite for depending from an indefinite claim.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 1, 3, 8-10, 21-23, and 25 are rejected under 35 U.S.C. 103 as being unpatentable over Luong (U.S. Patent Application Pub. No. 2020/0062865), in view of Van Loi et al. (Front Microbiol. 2018; 9: Article 3037).
Applicant Claims
Applicant’s elected subject matter is directed to an antimicrobial “material” comprising spherical particles with a diameter of at most 5 µm comprising a cellulose carrier at least partially coated with ruthenium oxide and silver oxide.
Determination of the Scope and Content of the Prior Art (MPEP §2141.01)
Luong discloses e.g. an antimicrobial “material” comprising spherical particles with a diameter of e.g. 3-10 nm comprising a cellulose carrier at least partially coated with antimicrobial agents (see e.g. abstract; paragraphs 0009, 0031, 0034).
Van Loi et al. disclose the AGXX antimicrobial coating that can be attached to various carrier surfaces including to e.g. glass and organic polymers, which may be in particle form; is composed of two transition metal oxides, ruthenium and silver; and provides a potent antimicrobial effect against a broad range of Gram-positive and Gram-negative bacteria, including antibiotic resistant nosocomial pathogens.
Ascertainment of the Difference Between the Scope of the Prior Art and the Claims (MPEP §2141.02)
Luong does not explicitly disclose that the antimicrobial agent coating the cellulose particles comprises ruthenium oxide and silver oxide. This deficiency is cured by the teachings of Van Loi et al.
Finding of Prima Facie Obviousness Rationale and Motivation
(MPEP §2142-2143)
It would have been prima facie obvious for one of ordinary skill in the art at the time the present application was filed to combine the respective teachings of Luong and Van Loi et al., outlined supra, to devise Applicant’s presently claimed composition.
Luong discloses e.g. an antimicrobial “material” comprising spherical particles with a diameter of e.g. 3-10 nm comprising a cellulose carrier at least partially coated with antimicrobial agents, for use in e.g. a wound dressing. Since Van Loi et al. disclose that the AGXX antimicrobial coating can be attached to various carrier surfaces including to e.g. glass and organic polymers, which may be in particle form; is composed of two transition metal oxides, ruthenium and silver; provides a potent antimicrobial effect against a broad range of Gram-positive and Gram-negative bacteria, including antibiotic resistant nosocomial pathogens; and thus has application in wound dressings; one of ordinary skill in the art would thus be motivated to employ the AGXX antimicrobial coating as the antimicrobial coating on the Luong cellulose particles, with the reasonable expectation that the resulting particles can be applied to a wound dressing to successfully provide a potent antimicrobial effect against a broad range of Gram-positive and Gram-negative bacteria, including antibiotic resistant nosocomial pathogens.
In light of the foregoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103(a).
From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.
Response to Arguments
Applicant's arguments filed September 10, 2026 have been fully considered but they are not persuasive.
i) Applicant contends that “the Office acknowledges that van Loi does not disclose AGXX microparticles to contain oxidation state VI…rather…RuO4 is used to create Ru or RuOx…wherein RuO2 has Ru in the IV oxidation state”; that “the prior art consistently teaches metallic Ru(0) and Ag(0), not semiconductive Ru(IV)/(VI) oxides or silver semiconductors, and provides no motivation to alter oxidation states”, and “Van Loi…explicitly describes AGXX as metallic ruthenium and metallic silver, not oxides”; that “the person skilled in the art would not be able to identify RuOx as a results-effective variable…to affect…here the antimicrobial effect”; and “AGXX…allows for electron flow and eventually the generation of reactive oxygen species (ROS) at the interface”.
The Examiner, however, would like to point out the following:
1. First, it is noted that the prior art rejection is over Luong in view of Van Loi, and Van Loi teaches the AGXX antimicrobial coating which is composed of e.g. two transition metal oxides, ruthenium and silver; and provides a potent antimicrobial effect. Whether the prior art before Van Loi consistently teaches metallic Ru(0) and Ag(0) is thus really of no consequence.
2. Applicant is not claiming a hybrid material in which the ruthenium compound is exclusively ruthenium VI. In stark contrast, Applicant’s claims provide, at the very least, that one of the ruthenium atoms is in oxidation state IV, or that at least one of the ruthenium atoms is in oxidation state VI. All of the ruthenium can be in oxidation state IV and none at all in oxidation state VI. Applicant’s claims are in fact broader than merely oxidation state IV or VI. In fact, Applicant’s claims provide that, in addition to the at least one ruthenium atom that is in e.g. oxidation state IV or e.g. in oxidation state VI, that ruthenium can also be in any other oxidation state, such as Ru(0). Indeed, as now presented, the claims provide that the majority of the ruthenium can even be Ru(0), as long as at least one ruthenium atom is in oxidation state IV, or in oxidation state VI.
3. Hence, Applicant’s claims basically provide that the ruthenium is expected to readily transition between oxidation states, as if in an environment where there are reactive oxygen species available that can react with the ruthenium and at various points in time the ruthenium is oxidized or reduced, and the environment is such that at least one ruthenium or even most of the ruthenium will be in the IV or VI oxidation state, or both.
4. As Applicant points out, the Office has acknowledged that Van Loi discloses manufacturing the AGXX coating by reduction of RuO4, in which ruthenium is in the VI oxidation state, to Ru or RuOx, wherein for RuO2 the ruthenium is in the IV oxidation state. However, as already mentioned, supra, Applicant’s claims are not limited to Ru being in the VI oxidation state. Rather, Applicant’s claims provide that Ru can be in the IV oxidation state only, and not the VI oxidation state. Ru can also, in addition to the IV oxidation state, be in the Ru(0) state.
5. Van Loi provides that the ruthenium can be in the IV oxidation state, in the Ru(0) state, or even in the VI oxidation state. RuOx would indeed include RuO2 (i.e. IV oxidation state) or RuO4 (i.e. VI oxidation state). Applicant has admitted on the record that “AGXX allows for electron flow and eventually the generation of reactive oxygen species (ROS) at the interface”. No doubt then in Van Loi the Ru is exposed to conditions that permit the oxidation and reduction of the Ru to various oxidation states. With the presence of ROS, the Ru will primarily be in the VI or IV oxidation state, or some combination, but could also be, at least in part, in the Ru(0) state. But Applicant’s claims provide precisely the very same limitations.
For the foregoing reasons, the 35 USC 103 rejection is hereby maintained.
Conclusion
No claims are allowed.
Inquiries
Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID BROWE whose telephone number is (571)270-1320. The examiner can normally be reached Monday - Friday, 9:30 AM to 6 PM EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sue Liu can be reached at 571-272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/DAVID BROWE/Primary Examiner, Art Unit 1617